

ALLOWANCE

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 28, 2009 has been entered.

2. Applicant's amendment filed January 28, 2009 is acknowledged and has been entered. Claims 1-37 and 39-55 have been canceled. Claims 56 and 59-61 have been amended. Claims 38 and 56-61 are now pending in the present application. All rejections have been withdrawn in view of Applicants' amendment to the claims and/or comments.

3. The application has been amended as follows:

1-37. (Cancelled)

38. (Previously presented) A composition comprising a modified GPI molecule, wherein said modified GPI molecule comprises a GPI inositolglycan domain but excludes a lipidic domain.

39-55. (Cancelled)

56. (Previously presented) A composition according to claim 38, wherein said modified GPI molecule is a modified parasite GPI molecule.

57. (Previously presented) A composition according to claim 56, wherein said parasite is Plasmodium.

58. (Currently amended) A composition according to claim 57, wherein said Plasmodium is *P.[falciparurn]* *falciparum*.

59. (Previously presented) A composition according to claim 38, wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Man α 1,2)-Man α 1,2 Man α 1,6 Man α 1,4 GlcN-myo-inositol phosphoglycerol.

60. (Previously presented) A composition according to claim 38, wherein said GPI inositolglycan domain comprises the structure

X1-X2-X3-X4-ethanolamine-phosphate-(Man α 1,2)-
Man α 1,2Man α 1,6Man α 1,4GlcN-myo-inositol phosphoglycerol
wherein X1, X2, X3 and X4 are any 4 amino acids.

61. (Currently amended) A composition according to claim 38, wherein said GPI inositolglycan domain comprises the structure

EtN-P-[M α 2]M α 2 M α 6 M α 4G α 6Ino

EtN-P-[M α 2][G]M α 2 M α 6 M α 4G α 6Ino

EtN-P-[M α 2][X]M α 2M α 6M α 4G α 6Ino

EtN-P-[M α 2][EtN-P]M α 2M α 6 M α 4G α 6Ino

EtN-P-M α 2 M α 6 M α 4G

[[M α 2 M α 6 M α G]]

M α 2 M α 6 M α 4G

EtN-P-M α 2 M α 6 M
EtN-P-[M α 2][G]M α 2 M α 6 M α 4G
EtN-P-[M α 2][X]M α 2 M α 6 M α 4G
EtN-P-[M α 2][EtN-P]M α 2 M α 6 M α 4G
M α 2 [M α 2][G]M α 2 M α 6 M α 4G
M α 2 [M α 2][X]M α 2 M α 6 M α 4G
M α 2 [M α 2][EtN-P]M α 6 M α 4G
M α 6 M α 4G α 6Ino
M α 2 M α 6 M α 4G α 6Ino
M α 2 [M α 2]M α 6 M α 4G α 6Ino
M α 2 [M α 2][G]M α 6 M α 4G α 6Ino
M α 2 [M α 2][X]M α 6 M α 4G α 6Ino
EtN-P-[M α 2][G]M α 2 M α 6 M
EtN-P-[M α 2][X]M α 2 M α 6 M
EtN-P-[M α 2][EtN-P]M α 2 M α 6 M
M α 2 [M α 2][G]M α 2 M α 6 M
M α 2 [M α 2][X]M α 2 M α 6 M
M α 2 [M α 2][EtN-P]M α 6 M
M α 2 M α 6 M
M α 6 M α 4G
EtN-P-[M α 2] [G]M α 2 M
EtN-P-[M α 2][X]M α 2 M
EtN-P-[M α 2][EtN-P]M α 2 M

wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substitute, α represent α -linkages which may be substituted with β -linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

4. Claims 38 and 56-61 have been allowed and renumbered 1-7 respectively.

5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert B. Mondesi can be reached on 571-272-0956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

N. M. Minnifield
Primary Examiner
Art Unit 1645

/N. M. Minnifield/
Primary Examiner, Art Unit 1645
April 8, 2009